Source: https://patents.google.com/patent/US20130282073A1/en
Timestamp: 2019-04-24 13:05:15
Document Index: 381496436

Matched Legal Cases: ['Application No. 60', 'Application No. 60', 'Application No. 60', 'Application No. 60', 'art.\n8', 'art.\n11']

US20130282073A1 - Leadless tissue stimulation systems and methods - Google Patents
US20130282073A1
US20130282073A1 US13/657,252 US201213657252A US2013282073A1 US 20130282073 A1 US20130282073 A1 US 20130282073A1 US 201213657252 A US201213657252 A US 201213657252A US 2013282073 A1 US2013282073 A1 US 2013282073A1
US13/657,252
US9008776B2 (en
2004-12-21 Priority to US63903704P priority
2005-12-21 Priority to US11/315,023 priority patent/US7610092B2/en
2009-09-04 Priority to US12/554,257 priority patent/US8315701B2/en
2012-10-22 Priority to US13/657,252 priority patent/US9008776B2/en
2012-10-22 Application filed by EBR Systems Inc filed Critical EBR Systems Inc
2013-10-24 Publication of US20130282073A1 publication Critical patent/US20130282073A1/en
2015-04-14 Publication of US9008776B2 publication Critical patent/US9008776B2/en
This application is a divisional of U.S. patent application Ser. No. 12/554,257 (Attorney Docket No. 41567-708.401), filed on Sep. 4, 2009, which is a divisional of U.S. application Ser. No. 11/315,023 (Attorney Docket No. 41567-708.201), filed on Dec. 21, 2005, now issued U.S. Pat. No. 7,610,092, which claims the benefit and priority of the following: U.S. Provisional Application No. 60/689,606 (Attorney Docket No. 41567-708.102), filed on Jun. 9, 2005; U.S. Provisional Application No. 60/639,027 (Attorney Docket No. 41567-708.101), filed on Dec. 21, 2004; and U.S. Provisional Patent Application No. 60/639,037 (Attorney Docket No. 41567-709.101), filed on Dec. 21, 2004, the full disclosures of which are incorporated herein by reference.
The subject matter of this application is also related to that of application Ser. No. 11/315,524 (Attorney Docket No. 41567-710.201), filed on Dec. 21, 2005, which claims the benefit of Provisional Application No. 60/639,056 (Attorney Docket No. 41567-710.101), filed on Dec. 21, 2004, the full disclosures of which are incorporated herein by reference.
It would also be beneficial to provide more physiological right ventricular pacing for patients without HF. In normal physiology, the right ventricle is first stimulated in the upper septal area, and then the impulse travels down specially conducting pathways to the right ventricular apex.
However, pacing the right ventricle is virtually always accomplished from a lead tip electrode located in the right ventricular apex, such that the subsequent conduction pathway is abnormal and slow. Clinical trials have recently shown that in patients with and without A-V block, pacing from the right ventricular apex can result in increased total mortality and re-hospitalization for heart failure. Thus it would be advantageous to be able to pace the right ventricle at more physiological locations such as the upper septum. The most physiological location to pace the ventricle in patients with sinus nodal or A-V junction conduction disease is to directly pace the His bundle. However, this location is very difficult to access from the superior (vena cava) approach mandated by lead-based systems that attach to a pectorally implanted pulse generator. It would be beneficial to deliver electrodes from the inferior (vena cava) approach via the femoral veins, in which catheter positioning in the A-V junction region is known to be easier. For instance, in a published series of permanent His bundle pacing, the His bundle was first identified using a temporary catheter inserted via the femoral vein, and this catheter was left in place to mark the location to target the site to implant the permanent pacing lead. In patients with lower conduction disease involving the A-V junction or bundle branches, the most physiological pacing sites have been found to be the left ventricular septum or left ventricular apex. These are locations in proximity to the specialized Purkinje conduction network. These locations are not accessible using current transvenous lead-based pacing systems. It would be advantageous to be able to select the pacing site in order to model more normal conduction.
Johnson P L, Newton J C, Rollins D L, Smith S M, Ideker RE, “Adaptive Pacing during Ventricular Fibrillation, PACE 2003; 26:1824-36
Ansalone G, Giannantoni P, Ricci R, Trambaiolo P, Fedele F, Santini M, “Bi-ventricular pacing I heart failure:back to basics in the pathophysiology of left bundle branch block to reduce the number of nonresponders,” Am J Cardiol 2003; 91:55 F-61F
Deshmukh P M and Romanyshyn M, “Direct His-bundle pacing: present and future,” PACE 2004; 27 [Pt.II]:862-70
TABLE-US-00001 Parameter Value Range Ultrasound frequency 20 kHz-10 MHz Burst Length (#cycles) 2-10,000 Stimulation Pulse Duration 0.1.mu.S-10 mS Duty Cycle 0.01-0.2% Mechanical Index .ltoreq.1.9
4. A system as in claim 1, wherein the implantable receiver-stimulator is adapted to be placed and secured at a location that optimally terminates the tachyarrhythmia.
5. A system as in claim 4, wherein the implantable receiver-stimulator is adapted to be placed and secured at a location within the tissue which is in a conduction pathway of the tachyarrhythmia.
6. A system as in claim 1, wherein the implantable receiver-stimulator is adapted to be placed and secured at a location that optimally prevents a tachyarrhythmia.
7. A system as in claim 1, wherein the implantable receiver-stimulator is adapted to be placed and secured at a location within the tissue which is in the normal conduction pathway of the heart.
8. A system as in claim 1, where in the implantable receiver-stimulator is placed and secured at any location within a cardiac chamber.
9. A system as in claim 1, where in the implantable receiver-stimulator is placed and secured at any location within myocardial tissue.
10. A system as in claim 1, wherein the implantable receiver-stimulator is placed and secured at a location on the epicardial aspects of the heart.
11. A system as in claim 1, wherein two or more receiver-stimulators are placed and secured in locations that optimally prevent or terminate the tachyarrhythmia.
12. A system as in claim 1, wherein the controller-transmitter processes the electrocardiogram to determine the presence or absence of a tachyarrhythmia.
13. A system as in claim 12, wherein the determination of the presence or absence of a tachyarrhythmia is based on heart rate or electrogram waveform morphology.
14. A system as in claim 1, wherein the controller-transmitter is adapted to transmit acoustic energy to at least one of the receiver-stimulator(s) when tachyarrhythmia is detected.
US13/657,252 2004-12-21 2012-10-22 Leadless tissue stimulation systems and methods Active US9008776B2 (en)
US63903704P true 2004-12-21 2004-12-21
US11/315,023 US7610092B2 (en) 2004-12-21 2005-12-21 Leadless tissue stimulation systems and methods
US12/554,257 US8315701B2 (en) 2004-12-21 2009-09-04 Leadless tissue stimulation systems and methods
US12/554,257 Division US8315701B2 (en) 2004-12-21 2009-09-04 Leadless tissue stimulation systems and methods
US9008776B2 US9008776B2 (en) 2015-04-14
US11/315,023 Active 2027-07-05 US7610092B2 (en) 2004-12-21 2005-12-21 Leadless tissue stimulation systems and methods
US12/554,234 Active US7996087B2 (en) 2004-12-21 2009-09-04 Leadless tissue stimulation systems and methods
US12/554,257 Active 2027-03-27 US8315701B2 (en) 2004-12-21 2009-09-04 Leadless tissue stimulation systems and methods
US13/657,252 Active US9008776B2 (en) 2004-12-21 2012-10-22 Leadless tissue stimulation systems and methods
WO (1) WO2006069215A2 (en)
WO2015171760A1 (en) * 2014-05-06 2015-11-12 Medtronic, Inc. Triggered pacing system
2005-12-21 WO PCT/US2005/046532 patent/WO2006069215A2/en active Application Filing
2005-12-21 EP EP05855143.3A patent/EP1835964B1/en active Active
2005-12-21 JP JP2007548461A patent/JP5111116B2/en active Active
2005-12-21 US US11/315,023 patent/US7610092B2/en active Active
2009-09-04 US US12/554,234 patent/US7996087B2/en active Active
2009-09-04 US US12/554,257 patent/US8315701B2/en active Active
2011-10-13 JP JP2011226036A patent/JP5462848B2/en active Active
2012-06-05 JP JP2012128159A patent/JP2012196485A/en not_active Withdrawn
2012-10-22 US US13/657,252 patent/US9008776B2/en active Active
CN106255529A (en) * 2014-05-06 2016-12-21 美敦力公司 Triggered pacing system
US20100063562A1 (en) 2010-03-11
US20060136004A1 (en) 2006-06-22
US8315701B2 (en) 2012-11-20
US7610092B2 (en) 2009-10-27
JP2008525115A (en) 2008-07-17
JP2012011232A (en) 2012-01-19
WO2006069215A3 (en) 2009-06-18
EP1835964A2 (en) 2007-09-26
EP1835964A4 (en) 2010-06-02
EP1835964B1 (en) 2016-03-09
US9008776B2 (en) 2015-04-14
US20100228308A1 (en) 2010-09-09
JP5462848B2 (en) 2014-04-02
JP5111116B2 (en) 2012-12-26
JP2012196485A (en) 2012-10-18
US7996087B2 (en) 2011-08-09
WO2006069215A2 (en) 2006-06-29
US20080097543A1 (en) 2008-04-24 Cardiac rhythm management system and method
US20040138710A1 (en) 2004-07-15 Signal delivery through the right ventricular septum